Redeye embraces BONESUPPORT’s Q1 report, showing a remarkable growth of 48% y/y, primarily driven by...
Redeye comments on Aspire’s Q1-results which came in slightly above expectations driven by strong pe...
Redeye comments on Stillfront’s Q1-results which came in above our expectations although with somewh...
The CMD added color on Enersense’s plans to expand its print in the renewables value chain.
Q1 earnings were better than feared, but substantially higher-than-expected cost headwinds create un...
Positive top line revisions while lowered NOI margin Borrowing terms should improve even with higher...
Guiding for -20% q-o-q growth in Integrated Solutions… …and largest customer might switch to dual so...
NAVPS (SEK) flat q-o-q and up 55% y-o-y in Q1’22 Trading at 45% discount to NAVPS Fair value rang...
Redeye comments on Lipigon’s first-quarter report in 2022.
Organic sales +4.4% y-o-y, adj. EBIT margin 13.2% (11%) Positive EBIT revisions from raised profitab...
Redeye is encouraged by the positive End-of-Phase I meeting with the FDA and provides a brief commen...
The Prostatype Genomics Board has proposed a SEK 22.
Redeye comments on Pila Pharma’s new pipeline announcement and adjusts its fair value range ahead of...
Redeye estimates that Smart Eye’s ramp-up of revenues will be delayed by 1-2 quarters.
Redeye embraces AroCell’s Q1’22 report, demonstrating good cost control and higher sales than expect...
Redeye revises its fair value range after taking a closer look at Q1, an eventful quarter which saw ...
Redeye retains its positive view towards Efecte following a Q1 report in line with our expectation, ...
Redeye retains its positive view of Binero while making minor forecast adjustments following its Q1’...
Redeye's first impressions on the Q1 report from Bioservo earlier this morning.
Sales 2% below and GM of 51% vs ABGSC at 70% Reiterates 2022 outlook with GM of 69-70% Expect small ...
